Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
Rutgeerts
P
P
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005938:Glucocorticoids; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D019804:Mesalamine; D019819:Budesonide